// App-Quantinova.ai

2063 : Phase I/II study of VAL-083 in patients with recurrent glioblastoma.

Researchers

Presenter

  • Kent C. Shih

Principal Investigators

  • Manish R. Patel

  • Nicholas A. Butowski

  • Gerald Steven Falchook

  • Sani Haider Kizilbash

  • Jeffrey A. Bacha

  • Dennis Brown

  • Anne Steino

  • Richard Stephen Schwartz

  • Sarath Kanekal

  • Lorena Lopez

  • Howard A. Burris

Medical Centers

  • Tennessee Oncology, Nashville, TN

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • University of California, San Francisco, San Francisco, CA

  • Sarah Cannon Research Institute, Denver, CO

  • Mayo Clinic, Rochester, MN

  • Del Mar Pharmaceuticals, Vancouver, BC, Canada

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Dianhydrogalactitol

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01478178

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved